The impact of non-medical switching among ambulatory patients: an updated systematic literature review

References

• H-125.991 Drug formularies and therapeutic interchange. Chicago, IL: American Medical Association; 2010. [cited 2018 Nov 1]. Available from: https://policysearch.ama-assn.org/policyfinder/detail/Drug%20Formularies%20and%20Therapeutic%20Interchange%20H-125.991?uri=%2FAMADoc%2FHOD.xml-0-227.xml
   Google Scholar
• Gray T, Bertch K, Galt K, et al. ACCP position statement: guidelines for therapeutic interchange – 2004. Pharmacotherapy. 2005;25:1666–15.
   PubMed Web of Science ®Google Scholar
• Nguyen E, Weeda ER, Sobieraj DM, et al. Impact of non-medical switching on clinical and economic outcomes, resource utilization and medication-taking behavior: a systematic literature review. Curr Med Res Opin. 2016;32:1–10.
   Web of Science ®Google Scholar
• Prior Authorization and Utilization Management Reform Principles. American Medical Association. 2017 [cited 2018 Nov 10]. Available from: https://www.ama-assn.org/sites/default/files/media-browser/principles-with-signatory-page-for-slsc.pdf
   Google Scholar
• Non-Medical Switching of Medications in Select States. Connecticut general assembly. Office of legislative research. 2017 [cited 2018 Nov 10]. Available from: https://www.cga.ct.gov/2017/rpt/pdf/2017-R-0201.pdf
   Google Scholar
• How utilization management protocols can block access to life-saving treatments. The doctor-patient rights project. 2018 [cited 2018 Nov 11]. Available from: http://dontswitchme.org/wp-content/uploads/2018/01/DPRP-UM-Report-1.pdf
   Google Scholar
• Promoting access to affordable prescription drugs: policy analysis and consumer recommendations for state policymakers, consumer advocates, and health care stakeholders. 2016 [cited 2018 Nov 11]. Available from: https://consumersunion.org/wp-content/uploads/2016/08/Promoting-Access-to-Affordable-Prescription-Drugs_Aug-2016.pdf
   Google Scholar
• Gibofsky A, Skup M, Mittal M, et al. Effects of non-medical switching on outcomes among patients prescribed tumor necrosis factor inhibitors. Curr Med Res Opin. 2017;33:1945–1953.
   PubMed Web of Science ®Google Scholar
• Rosenblatt L, Buikema AR, Seare J, et al. Economic outcomes of first-line regimen switching among stable patients with HIV. J Manag Care Spec Pharm. 2017;23:725–734.
   Web of Science ®Google Scholar
• Wolf D, Skup M, Yang H, et al. Clinical outcomes associated with switching or discontinuation from Anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39:849–862.
   PubMed Web of Science ®Google Scholar
• Blonde L, Burudpakdee C, Divino V, et al. The impact of non-medical switch on type 2 diabetes patients treated with Canagliflozin in the commercially insured US population. Curr Med Res Opin. 2018;34:1–21.
   Web of Science ®Google Scholar
• Flores NM, Patel CA, Bookhart BK, et al. Consequences of non-medical switch among patients with type 2 diabetes. Curr Med Res Opin. 2018;34:1475–1481.
   PubMed Web of Science ®Google Scholar
• Naville-Cook C, Rhea L, Triboletti M, et al. Analyzing the clinical outcomes of a rapid mass conversion from rosuvastatin to atorvastatin in a VA medical center outpatient setting. J Pharm Technol. 2017;33:189–194.
   Web of Science ®Google Scholar
• Boktor M, Motlis A, Aravantagi A, et al. Substitution with Alternative Anti-TNFα Therapy (SAVANT)-outcomes of a Crohn’s disease cohort undergoing substitution therapy with certolizumab. Inflamm Bowel Dis. 2016;22:1353–1361.
   PubMed Web of Science ®Google Scholar
• Yip E, Karimi S, Pien LT. Evaluation of a therapeutic interchange from fluticasone/salmeterol to mometasone/formoterol in patients with chronic obstructive pulmonary disease. J Manag Care Spec Pharm. 2016;22:316–323.
   Web of Science ®Google Scholar
• Andreoli MT, Pinnolis M, Kieser T, et al. Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. Digit J Ophthalmol. 2015;21:1–17.
   PubMedGoogle Scholar
• Asias BD, Stock EM, Small NL, et al. Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes. J Diabetes Metab Disord. 2015;14:53.
   PubMed Web of Science ®Google Scholar
• Low GA, Weilburg JB. Rockett H et al. Therapeutic substitution from atorvastatin to simvastatin: impact on LDL control. Am J Pharm Benefits. 2015;7:e37–e43.
   Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester, UK: John Wiley & Sons, 2019.
   Google Scholar
• Tsertsvadze A, Maglione M, Chou R, et al. Updating comparative effectiveness reviews: current efforts in AHRQ’s effective health care program. J Clin Epidemiol. 2011;64:1208–1215.
   Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute; 2014. [cited 2018 Oct 31]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Cheetham TC, Chan J, Benson V, et al. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug. Am J Manag Care. 2005;11:546–552.
   PubMed Web of Science ®Google Scholar
• Liu Y, Skup M, Lin J, et al. Impact of non-medical switching on healthcare costs: a claims database analysis. Value Health. 2015;18:A252.
   Web of Science ®Google Scholar
• Saseen JJ, Ghushcyan V, Kaila S, et al. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers. J Clin Hypertens. 2013;15:888–892.
   Web of Science ®Google Scholar
• Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health-Syst Pharm. 2000;57:1703–1708.
   PubMed Web of Science ®Google Scholar
• Gates R, Cookson T, Ito M, et al. Therapeutic conversion from fosinopril to benazepril at a Veterans Affairs medical center. Am J Health-Syst Pharm. 2006;63:1066–1068.
   PubMed Web of Science ®Google Scholar
• Billups SJ, Plushner SL, Olson KL, et al. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm. 2005;11:681.
   PubMedGoogle Scholar
• Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy. 2003;23:1508–1512.
   PubMed Web of Science ®Google Scholar
• Graham MR, Allcock NM. Irbesartan substitution for valsartan or losartan in treating hypertension. Ann Pharmacother. 2002;36:1840–1844.
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy. 2001;21:1130–1139.
   PubMed Web of Science ®Google Scholar
• Good CB, Fultz SL, Trilli L, et al. Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization. Am J Manag Care. 2000;6:1141–1146.
   PubMed Web of Science ®Google Scholar
• Oatis MGM, Stowers AD. Conversion from amlodipine to felodipine ER: did the change fulfill expectations? Formulary. 2000;35:435–442.
   Google Scholar
• Kamal KM, Zacker C, Civitarese L. Switching between different ARBs in patients with controlled BP. Am J Pharm Benefits. 2012;4:e81–7.
   Google Scholar
• Signorovitch J, Bao Y, Samuelson T, et al. Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: impact on health care service use. Ann Rheum Dis. 2012;71(suppl3):717.
   Google Scholar
• West JC, Rae DS, Mojtabai R, et al. Clinically unintended medication switches and inability to prescribe preferred medications under Medicare Part D. J Psychopharmacol. 2012;26:784–793.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Yu AP, Lauzon V, et al. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother. 2011;45:441–451.
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Zhang J, Wu EQ, et al. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. Curr Med Res Opin. 2010;26:849–860.
   PubMed Web of Science ®Google Scholar
• Bryant GA, McDanel DL, Horner KE, et al. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir. Pharmcotherapy. 2013;33:56–62.
   PubMed Web of Science ®Google Scholar
• Alemayehu B, Ke X, Youssef NN, et al. Esomeprazole formulary exclusion: impact on total health care services use and costs. Postgrad Med. 2012;124:149–163.
   PubMed Web of Science ®Google Scholar
• Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008;28:553–561.
   PubMed Web of Science ®Google Scholar
• Meissner B, Dickson M, Shinogle J, et al. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331.
   PubMed Web of Science ®Google Scholar
• Tran F, Boggie DT, Delattre ML, et al. Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. Am J Health-Syst Pharm. 2004;61:1391–1394.
   PubMed Web of Science ®Google Scholar
• Andrade SE, Gurwitz JH, Cernieux J, et al. Evaluation of a formulary switch from conjugated to esterified estrogens in a managed care setting. Med Care. 2000;38:970–975.
   PubMed Web of Science ®Google Scholar
• Clay DR, Bourg MP, Lawrence DB. Outcomes of an amlodipine-to-felodipine therapeutic interchange program. Am J Health-Syst Pharm. 2000;57:1604–1607.
   PubMed Web of Science ®Google Scholar
• Mamdani MM, Reisig CJ, Stevenson JG. Cost analysis of therapeutic interchange of calcium channel blockers for the treatment of hypertension: unexpected results from a conversion program. J Manag Care Pharm. 2000;6:390–394.
   Google Scholar
• Nelson WW, Vermeulen LC, Geurkink EA, et al. Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. Arch Intern Med. 2000;160:2491–2496.
   PubMed Web of Science ®Google Scholar
• Parra D, Beckey NP, Korman L. Retrospective evaluation of conversion of amlodipine to alternative calcium channel blockers. Pharmacotherapy. 2000;20:1072–1078.
   PubMed Web of Science ®Google Scholar
• Walters J, Noel H, Folstad J, et al. Prospective evaluation of the therapeutic interchange of felodipine ER for amlodipine in patients with hypertension. Hosp Pharm. 2000;35:48–51.
   Google Scholar
• Cote BR, Petersen EA. Impact of therapeutic switching in long-term care. Am J Manag Care. 2008;14:SP23–8.
   PubMed Web of Science ®Google Scholar
• Special commission to study switching medications report to the massachusetts legislature. 2018 [cited 2018 Nov 10]. Available from: https://www.mass.gov/files/documents/2018/06/06/final-report-special-commission-report-on-medication-switching.pdf
   Google Scholar
• Global Healthy Living Foundation. Patient perspectives on medication switching for non-medical reasons: a survey of stabilized patients by the Global Healthy Living Foundation. Upper Nyack, NY: Global Healthy Living Foundation; 2015 [cited 2018 Nov 4]. Available from: http://www.50statenetwork.org/wp-content/uploads/2015/04/GHLF-Switching-Stable-Patients-Survey_Summary.pdf
   Google Scholar
• Ellingson L. Position on non-medical switching for diabetes patients. J Diabetes Metab Disord Control. 2017;4:138‒139.
   Google Scholar
• Access to Care Position Statement. Lupus and Allied Disease Associations, Inc cited 2018 Nov 10 Available from: http://www.nolupus.org/LADAFinalAccessPosition.pdf
   Google Scholar
• Issue Brief: Non-medical switching and step therapy. Hemophilia foundation of America. 2016 [cited 2018 Nov 10]. Available from: http://www.hemophiliafed.org/uploads/PGR_IssueBrief_NonMedicalSwitching_2016-10-25.pdf
   Google Scholar
• Cochrane. Editorial and publishing policy resource, 2016 [cited 2018 Nov 1]. Available from: http://community.cochrane.org/editorial-and-publishing-policy-resource
   Google Scholar
• Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. BMJ. 2016;354:i3507.
   PubMedGoogle Scholar
• Bikdeli B, Punnanithinont N, Akram Y, et al. Two decades of cardiovascular trials with primary surrogate endpoints: 1990–2011. J Am Heart Assoc. 2017;6:1–9.
   Web of Science ®Google Scholar